Therefore, combining MDRVV with tepotinib is expected to provide complementary effects: MDRVV triggers tumor-specific immune activation, while MET inhibition reduces immunosuppressive signals in the tumor microenvironment. The gene discussed is MET; the disease is neoplasm.